Evolved resistance to tyrosine kinase inhibitor (TKI)-targeted therapies remains a major
clinical challenge. In epidermal growth factor receptor (EGFR) mutant non-small-cell lung …

Acquired resistance inevitably limits the curative effects of epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs), which represent the classical paradigm of molecular …

Somatic alterations in the epidermal growth factor receptor gene (EGFR) result in aberrant
activation of kinase signaling and occur in∼ 15% of non-small cell lung cancers (NSCLC) …

Simple Summary Lung cancer is the major cause of cancer-related deaths worldwide. The
development of targeted therapies has dramatically improved the outcome of lung cancer …

Tumor heterogeneity underlies resistance to tyrosine kinase inhibitors (TKI) in lung cancers
harboring EGFR mutations. Previous evidence suggested that subsets of preexisting …

Acquired resistance to EGF receptor (EGFR) tyrosine kinase inhibitor (TKI) is a critical
problem in the treatment of lung cancer. Although several mechanisms have been shown to …

While the development of EGFR-targeted tyrosine kinase inhibitors (TKIs) has revolutionized
treatment of EGFR mutation-positive non-small-cell lung cancer, acquired resistance to …

The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene
and development of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm …

Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors
(TKIs) is highly effective in terms of tumor response rate, survival, and quality of life …

EGFR-mutated lung cancers account for a significant subgroup of non–small cell lung
cancers overall. Third-generation EGFR tyrosine kinase inhibitors (TKI) are mutation …